Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Trabectedin Inhibits EWS-FLI1 and Evicts SWI/SNF from Chromatin in a Schedule-dependent Manner.

Harlow ML, Chasse MH, Boguslawski EA, Sorensen KM, Gedminas JM, Kitchen-Goosen SM, Rothbart SB, Taslim C, Lessnick SL, Peck AS, Madaj ZB, Bowman MJ, Grohar PJ.

Clin Cancer Res. 2019 Jun 1;25(11):3417-3429. doi: 10.1158/1078-0432.CCR-18-3511. Epub 2019 Feb 5.

PMID:
30723142
2.

A phase I/II trial and pharmacokinetic study of mithramycin in children and adults with refractory Ewing sarcoma and EWS-FLI1 fusion transcript.

Grohar PJ, Glod J, Peer CJ, Sissung TM, Arnaldez FI, Long L, Figg WD, Whitcomb P, Helman LJ, Widemann BC.

Cancer Chemother Pharmacol. 2017 Sep;80(3):645-652. doi: 10.1007/s00280-017-3382-x. Epub 2017 Jul 22.

3.

Wnt Signaling in Ewing Sarcoma, Osteosarcoma, and Malignant Peripheral Nerve Sheath Tumors.

Pridgeon MG, Grohar PJ, Steensma MR, Williams BO.

Curr Osteoporos Rep. 2017 Aug;15(4):239-246. doi: 10.1007/s11914-017-0377-9. Review.

PMID:
28647886
4.

Advances in the Treatment of Pediatric Bone Sarcomas.

Grohar PJ, Janeway KA, Mase LD, Schiffman JD.

Am Soc Clin Oncol Educ Book. 2017;37:725-735. doi: 10.14694/EDBK_175378. Review.

5.

Trabectedin Followed by Irinotecan Can Stabilize Disease in Advanced Translocation-Positive Sarcomas with Acceptable Toxicity.

Herzog J, von Klot-Heydenfeldt F, Jabar S, Ranft A, Rossig C, Dirksen U, Van den Brande J, D'Incalci M, von Luettichau I, Grohar PJ, Berdel WE, Burdach S.

Sarcoma. 2016;2016:7461783. Epub 2016 Oct 24.

6.

Lurbinectedin Inactivates the Ewing Sarcoma Oncoprotein EWS-FLI1 by Redistributing It within the Nucleus.

Harlow ML, Maloney N, Roland J, Guillen Navarro MJ, Easton MK, Kitchen-Goosen SM, Boguslawski EA, Madaj ZB, Johnson BK, Bowman MJ, D'Incalci M, Winn ME, Turner L, Hostetter G, Galmarini CM, Aviles PM, Grohar PJ.

Cancer Res. 2016 Nov 15;76(22):6657-6668. doi: 10.1158/0008-5472.CAN-16-0568. Epub 2016 Oct 3.

7.

18F-FLT Positron Emission Tomography (PET) is a Pharmacodynamic Marker for EWS-FLI1 Activity and Ewing Sarcoma.

Osgood CL, Tantawy MN, Maloney N, Madaj ZB, Peck A, Boguslawski E, Jess J, Buck J, Winn ME, Manning HC, Grohar PJ.

Sci Rep. 2016 Sep 27;6:33926. doi: 10.1038/srep33926.

8.

Identification of Mithramycin Analogues with Improved Targeting of the EWS-FLI1 Transcription Factor.

Osgood CL, Maloney N, Kidd CG, Kitchen-Goosen S, Segars L, Gebregiorgis M, Woldemichael GM, He M, Sankar S, Lessnick SL, Kang M, Smith M, Turner L, Madaj ZB, Winn ME, Núñez LE, González-Sabín J, Helman LJ, Morís F, Grohar PJ.

Clin Cancer Res. 2016 Aug 15;22(16):4105-18. doi: 10.1158/1078-0432.CCR-15-2624. Epub 2016 Mar 15.

9.

Englerin A Inhibits EWS-FLI1 DNA Binding in Ewing Sarcoma Cells.

Caropreso V, Darvishi E, Turbyville TJ, Ratnayake R, Grohar PJ, McMahon JB, Woldemichael GM.

J Biol Chem. 2016 May 6;291(19):10058-66. doi: 10.1074/jbc.M115.701375. Epub 2016 Mar 9.

10.

Functional Genomic Screening Reveals Splicing of the EWS-FLI1 Fusion Transcript as a Vulnerability in Ewing Sarcoma.

Grohar PJ, Kim S, Rangel Rivera GO, Sen N, Haddock S, Harlow ML, Maloney NK, Zhu J, O'Neill M, Jones TL, Huppi K, Grandin M, Gehlhaus K, Klumpp-Thomas CA, Buehler E, Helman LJ, Martin SE, Caplen NJ.

Cell Rep. 2016 Jan 26;14(3):598-610. doi: 10.1016/j.celrep.2015.12.063. Epub 2016 Jan 14.

11.

Targeting the EWS-FLI1 transcription factor in Ewing sarcoma.

Tancredi R, Zambelli A, DaPrada GA, Fregoni V, Pavesi L, Riccardi A, Burdach S, Grohar PJ, D'Incalci M.

Cancer Chemother Pharmacol. 2015 Jun;75(6):1317-20. doi: 10.1007/s00280-015-2726-7. Epub 2015 Mar 26.

PMID:
25809543
12.

Dual targeting of EWS-FLI1 activity and the associated DNA damage response with trabectedin and SN38 synergistically inhibits Ewing sarcoma cell growth.

Grohar PJ, Segars LE, Yeung C, Pommier Y, D'Incalci M, Mendoza A, Helman LJ.

Clin Cancer Res. 2014 Mar 1;20(5):1190-203. doi: 10.1158/1078-0432.CCR-13-0901. Epub 2013 Nov 25.

13.

Loss-of-function screen in rhabdomyosarcoma identifies CRKL-YES as a critical signal for tumor growth.

Yeung CL, Ngo VN, Grohar PJ, Arnaldez FI, Asante A, Wan X, Khan J, Hewitt SM, Khanna C, Staudt LM, Helman LJ.

Oncogene. 2013 Nov 21;32(47):5429-38. doi: 10.1038/onc.2012.590. Epub 2013 Jan 14.

14.

Prospects and challenges for the development of new therapies for Ewing sarcoma.

Grohar PJ, Helman LJ.

Pharmacol Ther. 2013 Feb;137(2):216-24. doi: 10.1016/j.pharmthera.2012.10.004. Epub 2012 Oct 18. Review.

PMID:
23085431
15.

Identification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by high-throughput screening.

Grohar PJ, Woldemichael GM, Griffin LB, Mendoza A, Chen QR, Yeung C, Currier DG, Davis S, Khanna C, Khan J, McMahon JB, Helman LJ.

J Natl Cancer Inst. 2011 Jun 22;103(12):962-78. doi: 10.1093/jnci/djr156. Epub 2011 Jun 8.

16.

Ecteinascidin 743 interferes with the activity of EWS-FLI1 in Ewing sarcoma cells.

Grohar PJ, Griffin LB, Yeung C, Chen QR, Pommier Y, Khanna C, Khan J, Helman LJ.

Neoplasia. 2011 Feb;13(2):145-53.

17.

The role of cytidine deaminase and GATA1 mutations in the increased cytosine arabinoside sensitivity of Down syndrome myeloblasts and leukemia cell lines.

Ge Y, Jensen TL, Stout ML, Flatley RM, Grohar PJ, Ravindranath Y, Matherly LH, Taub JW.

Cancer Res. 2004 Jan 15;64(2):728-35.

18.

Soluble 2-substituted aminopyrido[2,3-d]pyrimidin-7-yl ureas. Structure-activity relationships against selected tyrosine kinases and exploration of in vitro and in vivo anticancer activity.

Schroeder MC, Hamby JM, Connolly CJ, Grohar PJ, Winters RT, Barvian MR, Moore CW, Boushelle SL, Crean SM, Kraker AJ, Driscoll DL, Vincent PW, Elliott WL, Lu GH, Batley BL, Dahring TK, Major TC, Panek RL, Doherty AM, Showalter HD.

J Med Chem. 2001 Jun 7;44(12):1915-26.

PMID:
11384237
19.

Unique structural and stabilizing roles for the individual pseudouridine residues in the 1920 region of Escherichia coli 23S rRNA.

Meroueh M, Grohar PJ, Qiu J, SantaLucia J Jr, Scaringe SA, Chow CS.

Nucleic Acids Res. 2000 May 15;28(10):2075-83.

Supplemental Content

Loading ...
Support Center